Document:

Primus Therapeutics: Exhibit 10.13 - Filed by newsfilecorp.com

Exhibit 10.13

INDEMNIFICATION AGREEMENT 

 This INDEMNIFICATION AGREEMENT is made and entered into as of this [ ] day of
[ ], [ ], by and between PRIMUS THERAPEUTICS, INC., a corporation organized and existing under the laws of the state of Delaware with its principal office at 23 Orchard Road, Suite 105, Skillman, NJ 08558 (the “Company”), and [ ],
an individual residing at [ ] and a member of the Company’s Board of Directors (the “Director”). 

 WHEREAS the Company intends to file a Registration Statement on Form S-1 with the United States Securities and Exchange Commission and will apply to have its common stock listed on the Nasdaq Capital Market (or such other market as the Company may
in the future determine);

 WHEREAS the Company and the Director each recognize the substantial risk of litigation and other claims being asserted against directors of public companies;

 WHEREAS the Company recognizes that, in order to attract and retain persons of the highest caliber to serve as directors of the Company, it is in the best interests of the Company to provide for the indemnification, advancement, reimbursement and
insurance of certain liabilities and expenses of its directors, to the fullest extent permitted by law; and 

 WHEREAS the Director’s agreement to be appointed to, and continue to serve on, the Company’s board of directors is specifically conditioned upon the Company’s agreement to provide such indemnification; 

 NOW, THEREFORE, in consideration of these premises and of the mutual covenants herein contained, the parties hereto agree as follows:

1. Agreement to Serve as Director. The Director hereby agrees to serve as a director of the Company (and to serve on, and to act as Chairman, of such standing or ad hoc committees of the Board of Directors
may from time to time reasonably request) for so long as the Director is duly elected or appointed or until he tenders his resignation or is removed. The Director covenants to discharge his duties as a director faithfully and to the best of his
ability. 

2. Fees and Expenses. The Director shall be compensated for his services according to policies established from time to time by the Board of Directors, provided, however that in the event the Director is
or becomes an employee of the Corporation or any affiliate, he shall not be entitled to receive additional compensation for his service as a director. The Company shall promptly reimburse the Director, upon submission of receipts or other supporting
documentation, for all reasonable expenses incurred in performing his duties as a director.

3. Indemnification Against Liability. The Director shall be indemnified and held harmless by the Company, to the fullest extent permitted by law, against any and all liabilities and assessments arising out of or
related to any threatened, pending or completed action, suit, proceeding, inquiry or investigation, whether civil, criminal, administrative or other (each being hereinafter referred to as an “Action”), including, but not limited to,
judgments, fines, penalties and amounts paid in settlement (whether with or without court approval), and any interest,
assessments, excise taxes or other charges paid or payable in connection with or in respect of any of the foregoing (each such liability and assessment being hereinafter referred to as a “Liability”), incurred by the Director and
arising out of his status as a director or member of a committee of the Board of Directors of the Company, or by reason of anything done or not done by the Director in such capacities. 

4.  Indemnification Against Expense. The Director shall also be indemnified and held harmless by the Company, to the fullest extent permitted by law, against any and all attorneys' fees and other costs, expenses
and obligations, and any interest, assessments, excise taxes or other charges paid or payable in connection with or in respect of any of the foregoing (each such expense being hereinafter referred to as an “Expense”) arising out of
or relating to any Action, including expenses incurred by a Director:

	
 	
(a) 		
in connection with investigating, defending, being a witness or participating in, or preparing to defend, be a witness or participate in, any Action (other than an Action commenced by the Director against another party, except as
provided in Section 4(b) below) or any appeal of an Action; or

	
	 	 	 
	
 	
(b) 		
in connection with any claim asserted or action brought by the Director for (i) payment or indemnification of Liabilities or Expenses or advance payment of Expenses by the Company under this Agreement, or pursuant to any other
agreement, any resolution of the Company’s shareholders or Board of Directors, any provision of the Company’s Amended and Restated Certificate of Incorporation or Bylaws, or any statute or rule of law providing for indemnification, now or
hereafter in effect, relating to any Action, or for specific performance pursuant to Section 20 hereof, and/or (ii) recovery under any directors’ and officers’ liability insurance policy or policies maintained by the Company, in each case
regardless of whether the Director is ultimately determined to be entitled to such payment, indemnification, advance or insurance recovery, as the case may be.

	

5. Exception for Certain Conduct. The Company shall not be liable under this Agreement for payment of any Liability or Expense incurred by the Director on account of acts that, at the time taken, were known or
believed by the Director to be clearly in conflict with the Company's best interests. 

6. Partial Indemnification. If the Director is entitled under this Agreement to payment for some or a portion of any Liability or Expense relating to an Action, but not for the total amount thereof, the Company
shall nevertheless pay the Director for the portion thereof to which he or she is entitled. 

7. Advances. The Company shall pay any and all Expenses incurred by the Director in connection with any Action, whether or not the Action has been finally disposed of (an "Advance"), within five days after
receipt by the Company of an appropriate request therefor from the Director, provided, however, that the Company shall not make such an Advance unless
and until it has received an undertaking by or on behalf of the Director to repay such Advance unless it shall be determined that the Director is entitled to be indemnified by the Company against such Expenses. 

 - 2 -

8. Demand and Final Payment. Final payments of Liabilities and Expenses provided for herein shall be made by the Company not later than thirty days after receipt of a written request therefor by or on behalf of
the Director, and the Director shall be deemed to be entitled to indemnification against and payment of such Liabilities and Expenses unless a determination is made within said thirty-day period by (i) a majority vote of a quorum of the
Company’s Board of Directors, consisting of disinterested directors who are not parties to the Action giving rise to the demand, (ii) if such a quorum of disinterested directors so directs, by independent legal counsel in a written opinion, or
(iii) by majority vote of the Company’s shareholders, that Section 5 of this Agreement is applicable. The Director may contest a determination that he or she is not entitled to indemnification by petitioning a court to make an independent
determination with respect to the Director's right to indemnification hereunder.

9. Failure to Indemnify. If a claim for payment of any Liability, Expense or Advance under this Agreement, or pursuant to any other agreement, any resolution of the Company’s shareholders or Board of
Directors, any provision of the Company’s Amended and Restated Certificate of Incorporation or Bylaws, or any statute or rule of law providing for indemnification, now or hereafter in effect, is not paid in full within thirty days, in the case
of Liabilities and Expenses, or within five days, in the case of Advances, after a written request for payment thereof has been received by the Company, the Director may bring an action against the Company to recover the unpaid amount of such claim,
together with interest thereon. It shall be a defense to any such claim (other than an action brought to enforce a claim for an Advance) that the Director has not met the standard of conduct that makes it permissible under applicable law for the
Company to indemnify the Director for the amount claimed, provided, however , that the burden of proving such defense shall be on the Company and the Director shall be entitled to receive Advances pursuant to Section 7 hereof unless and until
such defense shall be finally adjudicated by a court.

10. Presumption. For purposes of this Agreement, the termination of any Action by judgment, order, settlement (whether with or without court approval) or conviction, or upon a plea of nolo contendere, or
its equivalent, shall not create a presumption that the Director has not met any particular standard of conduct required for payment under this Agreement.

11. Change in Control. If there is a Change in Control (as defined below) of the Company, then the acquiring or successor Person (as defined below), as the case may be (the “Successor”), shall
not diminish or limit in any manner the indemnification rights available to the Director immediately prior to such Change in Control, whether such rights were available under this Agreement or pursuant to any other agreement, any resolution of the
Company’s shareholders or Board of Directors, any provision of the Company’s Amended and Restated Certificate of Incorporation or Bylaws, or any statute or rule of law providing for indemnification, now or hereafter in effect. No such
Successor shall cancel, limit or in any way diminish the rights or coverage provided to the Director pursuant to one or more directors’ and officers’ insurance policies carried by the Company immediately prior to any such Change in
Control. For the purposes of this Agreement, the term “Change in Control” means (i) the
acquisition by any person or entity, or any group of persons or entities acting in concert (a “Person”), of direct or indirect beneficial ownership of forty percent (40%) or more of the voting power or voting securities of the
Company, (ii) the acquisition by any Person of direct or indirect beneficial ownership of twenty percent (20%) or more of the voting power or voting securities of the Company and the subsequent election of a majority of the members of the
Company’s Board of Directors who were not members of the Board for the two-year period immediately preceding their election, (iii) a transfer of all or substantially all of the Company’s assets to another Person other than a wholly owned
subsidiary of the Company, or (iv) the merger or consolidation of the Company with another corporation where, as a result of such merger and consolidation, less than sixty percent (60%) of the outstanding voting securities of the surviving or
resulting corporation shall then be owned by the shareholders of the Company immediately prior to such merger or consolidation. 

 - 3 -

12. Director's Obligations. The Director shall promptly notify the Company in writing of the initiation of any Action that may be the subject of a claim under this Agreement and shall keep the Company informed of
the progress of any such Action. Notices to the Company shall be directed to the Company at the following address: 

Primus Therapeutics, Inc. 

23 Orchard Road, Suite 105 

Skillman, NJ 08588 

Attention: Secretary 

or to such other address as the Company may notify the Director in writing. Notice shall be sent by overnight courier or by certified mail, postage repaid and return receipt requested. In addition, the Director shall give the Company such
information and cooperation as the Company shall reasonably require and as shall be in the Director's power.

13. Termination. This Agreement may not be terminated except by a writing to that effect executed by the parties hereto. This Agreement shall continue in effect indefinitely regardless of whether the Director
continues to serve as a director of the Company. 

14. Contract Rights Not Exclusive. The rights of the Director hereunder shall be in addition to, but not exclusive of, any other right which the Director may have pursuant to any other agreement, any resolution
of the Company's shareholders or Board of Directors, any provision of the Company's Restated Certificate of Incorporation or By-Laws, or any statute or rule of law providing for indemnification, now or hereafter in effect. 

15. Insurance. The rights of the Director hereunder shall also be in addition to any rights the Director may now or hereafter have under policies of insurance maintained by the Company or other wise. The Company
shall purchase and maintain in effect directors’ and officers’ liability insurance in an amount of at least One Million Dollars ($1,000,000) prior to the listing of the Company’s securities on any stock exchange, and Five Million
Dollars ($5,000,000) thereafter, against any liability asserted against or incurred by them, whether or not the Company would have the power to indemnify them against such liability, and the Director shall be covered by such policy or policies
to the maximum extent of the coverage available for any director of the Company. 

 - 4 -

16. Subrogation. In the event of any payment under this Agreement, the Company shall be subrogated to the extent of such payment to all of the rights of recovery of the Director, who shall execute all papers
required and shall do everything that may be necessary to secure such rights, including the execution of such documents as may be necessary to enable the Company effectively to bring suit to enforce such rights.

17. No Duplication of Payments. The Company shall not be liable under this Agreement to make any payment in connection with any claim made against the Director to the extent the Director has actually received
payment of the amounts otherwise payable hereunder.

18. Modification and Waiver. No supplement, modification or amendment of any of the provisions of this Agreement and no consent by either party hereto to any departure therefrom by the other party hereto shall be
binding unless executed in writing by both of the parties hereto. No waiver of any provision of this Agreement shall be deemed or shall constitute a waiver of any other provisions hereof (whether or not similar) nor shall any such waiver constitute
a continuing waiver. 

19. Binding Effect. This Agreement shall be binding upon and inure to the benefit of and be enforceable by the parties hereto and their respective successors and assigns (including any direct or indirect
successor by purchase, merger, consolidation or otherwise to all or substantially all of the business and/or assets of the Company) and spouses, heirs and personal and legal representatives. 

20. Specific Performance. The failure of the Company to perform any of its obligations hereunder shall entitle the Director, as a matter of course, to request an injunction from any court of competent
jurisdiction to enforce such obligations. Such right to request specific performance shall be cumulative and in addition to any other rights and remedies to which the Director shall be entitled.

21. Severability. If any provision or provisions of this Agreement, or any portion of any provision hereof, shall be deemed invalid or unenforceable pursuant to a final determination of any court of competent
jurisdiction or as a result of future legislative action, such determination or action shall be construed so as not to affect the validity or enforceability hereof, and the remaining provisions, and portions thereof, shall be enforceable to the
fullest extent permitted by law in a manner consistent with the intent of the parties. 

22. Governing Law. This Agreement shall be governed by and construed in accordance with the substantive laws of the State of Delaware. 

 IN WITNESS WHEREOF, the parties hereto have entered into this Agreement as of the date first above written.

PRIMUS THERAPEUTICS, INC. 

By: _________________
  Dennis M. O’Donnell 

 President & Chief Executive Officer 

[Name of Director] 

By: _________________
 

- 5 -Primus Therapeutics, Inc.: Exhibit 10.14 - Filed by newsfilecorp.com

PRIMUS THERAPEUTICS, INC. 

23 Orchard Road 
Suite 105

Skillman, NJ 08850 

[Date] 

[Lender]
[address] 
[address] 

Dear [Lender]: 

This letter agreement (the “Agreement”) confirms the
terms and conditions under which you (hereinafter “Lender”) have agreed
to lend to Primus Therapeutics, Inc., a Delaware corporation (the
“Company”), the sum specified on the signature page hereof (the
“Loan”): 

1. The Loan. Not later than one (1) Business Day
following the date of execution of this Agreement, Lender shall deposit to the
Company’s account, as specified in Schedule 1, by bank wire transfer of
immediately available funds, the principal amount of the Loan. In consideration
of the making of the Loan, the Company shall, immediately upon receipt of the
proceeds thereof, issue to Lender an unsecured convertible promissory note (the
“Note”), in the form attached hereto as Exhibit A. The Note shall
bear interest at the rate, shall mature on the maturity date (the “Maturity
Date”), and shall be prepayable at the time and in the manner, specified in
Exhibit A. This Agreement and the Note are referred to herein as the
“Transaction Documents”. For purposes of the Transaction
Documents, the term “Business Day” means any day other than a day upon
which banks in New York City are authorized or required by law to be closed.

2. Automatic Conversion. 

a. In the event that the Company completes an initial public
offering (an “Offering”) of its common stock prior to the Maturity Date,
the outstanding principal amount of the Loan, together with any and all accrued
but unpaid interest thereon (including default interest, if applicable)
(collectively, the “Loan Balance”) shall automatically be converted,
without further action by the Lender, into such number of shares of the
Company’s common stock (the “Applicable Number”) as shall be determined
by dividing the Loan Balance as of the day upon which the Offering is completed
by the Conversion Price. The Conversion Price shall be the amount determined by
multiplying the final price in such Offering by a factor of zero point seven
five (0.75) . The shares issued upon conversion of the Loan Balance are referred
to herein as the “Conversion Shares”. 

b. The Company shall reserve out of its authorized and unissued
Common Stock such number of shares of Common Stock as, in the judgment of the
Company exercised in good faith, will be sufficient to permit the conversion of
the Loan Balance. If at any time while the Note remains outstanding the Company
does not have a sufficient number of authorized and reserved shares of Common Stock to satisfy its
obligations pursuant to the preceding sentence, then the Company shall
immediately take all action necessary to increase the Company’s authorized
shares of Common Stock to comply with such obligations. 

[Lender] 
[Date] 
Page 2 

c. Not later than ten (10) Business Days following completion
of the Offering, and subject to the Lender having complied with its obligations
pursuant to clause d. of this paragraph, the Company shall cause its transfer
agent to issue the Applicable Number of Conversion Shares to the Lender. Unless
otherwise directed by Lender, such shares shall be issued in book entry form, in
the name of Lender, with the Lender’s address specified in paragraph 7.a. (or
such other address as Lender shall have furnished to the Company). Upon issuance
of the Applicable Number of Conversion Shares the Lender shall promptly
surrender the Note to the Company. Issuance of the Applicable Number of
Conversion Shares to the Lender shall fully discharge the obligations of the
Company under the Note. 

d. If in connection with an underwritten Offering any other
stockholders of the Company are required to enter into a lock-up agreement with
respect to their shares in the Company, the Lender shall, upon request from the
Company, enter into a lock-up agreement, on materially the same terms and
conditions, with respect to the Conversion Shares.

3. Registration Rights. 

a. If at any time following the Offering the Company proposes
to file a registration statement with the U.S. Securities and Exchange
Commission (the “Commission”) with respect to an offering of equity
securities, or securities or other obligations exercisable or exchangeable for,
on convertible into, equity securities, for its own account or for the account
of any stockholder of the Company (other than a registration statement on Form
S-4 or Form S-8 or their successors or any other form for a limited similar
purpose or any registration statement covering only securities proposed to be
issued in exchange for securities or assets of another person), the Company
shall, at least thirty days prior to such filing, give written notice to the
Lender of its intention to do so. Lender shall, not later than five (5) Business
Days following receipt of such notice, inform the Company in writing (i) the
number of Conversion Shares (if any) that Lender elects to have included in such
registration) and (ii) the intended method of disposition of such Conversion
Shares. The Company shall use its best efforts to cause the Conversion Shares
that the Lender requests the Company to register to be included in such
registration and shall use its reasonable best efforts to cause the managing
Underwriter or Underwriters (if any) of a proposed underwritten offering to
permit such Conversion Shares to be included in such registration on the same
terms and conditions as any similar securities of the Company, in each case to
the extent necessary to permit their sale or other disposition in accordance
with the intended methods of distribution specified in the request of Lender;
provided, however, that the Company shall have the right to postpone or
withdraw any registration effected pursuant to this Section without obligation
to the Lender and Lender may elect upon written notice to withdraw its
Conversion Shares from the registration. 

b. In connection with any underwritten offering under this
paragraph 3, the notice to the Lender specified in clause a. hereof shall state
whether such offering is an underwritten offering and the Company shall not be required to
include any Conversion Shares in such Underwriting Offering unless the Lender
accepts the terms of the underwriting agreed upon, in their absolute discretion,
by the Company and the managing underwriter or underwriters selected by the
Company. If Lender has requested that Conversion Shares held by it be included
in such Registration Statement Lender shall enter into such underwriting
agreement as the Company and the managing Underwriter or Underwriters may in
their absolute discretion negotiate. If, in the reasonable and good faith
opinion of the managing Underwriter or Underwriters, the registration of all, or
part of, the Conversion Securities requested to be included in such registration
and any other securities to be included in such registration jeopardize the
success of the offering by the Company or the holders of securities initiating
such registration, then (i) the Company shall not be cutback and (ii) the
Conversion Shares and any other securities requested for inclusion pursuant to
similar piggyback rights shall be reduced pro rata in accordance with the number
of securities that each such person has requested be included in the
registration.

[Lender] 
[Date] 
Page 3 

4. Representations and Warranties of the Company. The
Company hereby represents and warrants to Lender, subject to Schedule 3 hereof,
that, as of the date hereof and as of the date upon which the Equity Condition
is satisfied: 

a. The Company is duly organized, validly existing and in good
standing under the laws of the state of Delaware and has the requisite power and
authorization to own its properties and to carry on its business as now being
conducted.

b. The Company has the requisite corporate power and authority
to enter into and perform its obligations under the Transaction Documents and to
issue the Note in accordance with its terms. The execution and delivery of the
Transaction Documents by the Company and the consummation by the Company of the
transactions contemplated hereby and thereby, including, without limitation, the
issuance of the Note, the reservation for issuance and the issuance of the
Conversion Shares, have been duly authorized by the Company's board of directors
and (other than such filings as may be required by any state securities
agencies) no further filing, consent, or authorization is required by the
Company, its board of directors, its stockholders or any third party. The
Transaction Documents have been duly executed by the Company and (subject to
delivery and the execution and delivery of the Transaction Documents by Lender)
constitute the legal, valid and binding obligations of the Company, enforceable
against the Company in accordance with their respective terms, except as such
enforceability may be limited by general principles of equity or applicable
bankruptcy, insolvency, reorganization, moratorium, liquidation or similar laws
relating to, or generally affecting, creditors' rights and remedies. 

c. The issuance of the Note and the Conversion Shares have been
duly authorized and upon issuance in accordance with the terms of the
Transaction Documents shall be free from all taxes, liens, pre-emptive rights
and charges with respect thereto. Upon issuance, the Conversion Shares will be
validly issued, fully paid and non-assessable and free from all preemptive or
similar rights, taxes, liens and charges with respect to the issue thereof. 

[Lender] 

[Date] 

Page 4 

d. The execution, delivery and performance of the Transaction Documents by the Company and the consummation by the Company of the transactions contemplated hereby and thereby (including, without limitation, the issuance of the Note and the
Conversion Shares) will not (i) violate the Certificate of Incorporation or by-laws of the Company, or (ii) conflict with, or constitute a default (or an event that with notice or lapse of time or both would become a default) under, or give to
others any rights of termination, amendment, acceleration or cancellation of, any material agreement, indenture or instrument to which the Company is a party, or (iii) result in a violation of any material law, rule, regulation, order, judgment or
decree applicable to the Company or by which any property or asset of the Company is bound. 

5. Representations and Warranties of the Lender. Lender hereby represents and warrants to the Company as follows: 

a. Lender is acquiring the Note, and will (subject to satisfaction of the Equity Condition) be acquiring the Conversion Shares, in each case for [its/his/her] own account and not with a view towards, or for resale in connection with, the public sale
or distribution thereof, except pursuant to sales registered or exempted from registration under the Securities Act of 1933 (the “1933 Act”); 

b. Lender is an “accredited investor” as that term is defined in Rule 501(a) of Regulation D promulgated under the 1933 Act; 

c. Lender understands that the securities to be acquired by Lender pursuant to the Transaction Documents (the “Securities”), including without limitation the Conversion Shares, are being offered for sale and sold to Lender in
reliance upon specific exemptions from the registration requirements of Federal and state securities laws and that in determining the eligibility of Lender to acquire the Securities, the Company is relying in part upon the truth and accuracy of, and
Lender’s compliance with, the representations, warranties, agreements and acknowledgments of Lender set forth herein.

d. Lender and Lender’s advisers, if any, have been provided with all materials relating to the Company’s business operations, prospects and financial condition, and all materials relating to the offer and sale of the Securities, that
Lender has deemed necessary in order to make an informed investment decision with respect to an investment in the Securities. Lender and Lender’s advisers, if any, have been afforded the opportunity to ask questions of the Company and its
management regarding the same. Lender understands that Lender’s investment in the Securities involves a high degree of risk. Lender has sought such accounting, legal and tax advice as it has deemed necessary or appropriate in order to make an
informed decision regarding the purchase of the Securities, and is not relying on the Company for any such accounting, legal or tax advice. In making its decision to acquire the Securities, Lender has not relied upon any information other than
information provided to Lender by the Company and contained herein. 

[Lender] 

[Date] 

Page 5 

e. Lender understands that: (i) the Securities have not been registered under the 1933 Act or any state securities laws, are “restricted securities” as such term is defined in Rule 501 promulgated under the 1933 Act and may not be
offered for sale, sold, assigned or transferred unless (A) subsequently registered thereunder, (B) Lender shall have delivered to the Company an opinion of counsel, in a generally acceptable form, to the effect that any Securities to be sold,
assigned or transferred are exempt from registration, or (C) Lender provides the Company with reasonable assurance, including an opinion of counsel in a generally acceptable form that such Securities can be sold, assigned or transferred pursuant to
Rule 144 promulgated under the 1933 Act, as amended, or successor rules thereto (“Rule 144”); and (ii) any sale of Securities made in reliance upon Rule 144 may be made only in accordance with the terms thereof and further, if
Rule 144 is not applicable, any re-sale of Securities under circumstances in which the seller (or the person through whom or which the sale is made) may be deemed to be an underwriter for purposes of the 1933 Act and may require compliance with some
other exemption under the 1933 Act or the rules and regulations promulgated thereunder. 

f. Lender understands that the Note and (unless they have been registered under the 1933 Act) the certificates representing the Conversion Shares, shall bear any legend required by the “blue sky” laws of any state, and a restrictive
legend in substantially the following form: 

“THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS NOTE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR
ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN OPINION OF COUNSEL, IN A REASONABLY ACCEPTABLE FORM, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT
OR (II) UNLESS SOLD PURSUANT TO RULE 144 UNDER SAID ACT.”

 Lender further understands that the Note shall bear a legend stating that the sale, assignment or other transfer of the Note is subject to restrictions set forth in this Agreement. Lender understands (and the Company agrees) that upon the request
of the holder of the Securities, the legend set forth above shall be removed and the Company shall issue a certificate without such legend to the holder of said Securities if, unless otherwise required by state securities law, (i) such Securities
are registered for re-sale under the 1933 Act, (ii) in connection with a sale, assignment or other transfer, such holder provides the Company with an opinion of counsel, in a generally acceptable form, to the effect that such sale, assignment or
transfer of the Securities may be made without registration under the applicable provisions of the 1933 Act, or (ii) such holder provides the Company with reasonable assurance, including an opinion of counsel in a generally acceptable form, that the
Securities can be sold, assigned or transferred pursuant to Rule 144(b)(1)(i), without the need to comply with the requirements set forth in Rule 144(c)(1). 

g. Lender understands that neither the Commission nor any securities commission or other governmental authority of any state, country or other jurisdiction has
approved the issuance of the Securities or passed upon or endorsed the merits of
the Securities or this letter agreement, or confirmed the accuracy of,
determined the adequacy of, or reviewed this letter agreement or the Securities. 

[Lender] 
[Date] 
Page 6 

h. Lender is unaware of, and in deciding to purchase the
Securities is in no way relying upon, and did not become aware of the offer of
the Securities through or as a result of, any form of general solicitation or
general advertising including, without limitation, any article, notice,
advertisement or other communication published in any newspaper, magazine or
similar media, or broadcast over television or radio or the internet, in
connection with the offer of the Securities. 

6. Assignment, Transfer, etc. 

a. Lender may not be sell, assign or transfer and its rights
under this letter agreement or the Note other than (i) in compliance with
applicable securities laws and (ii) with the prior written consent of the
Company, provided, however, that (subject to clause b. hereof) Lender may
sell, assign or transfer the Note (in whole but not in part) upon prior written
notice to the Company to any Affiliate. For purposes of this Note, the term
“Affiliate” means (A) if the Lender is a juridical entity, any person
that controls, is controlled by or under common control with, Lender, and (B) if
the Lender is a natural person, any child, stepchild, grandchild, parent,
stepparent, grandparent, spouse, former spouse, sibling, niece, nephew,
mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or
sister-in-law of Lender, including adoptive relationships, any person sharing
the Holder’s household (other than a tenant or employee), a trust in which these
persons have more than fifty percent of the beneficial interest, a foundation in
which these persons (or Lender) control the management of assets, and any other
entity in which these persons (or Lender) own more than fifty percent of the
voting interests. 

b. It shall be a pre-condition to the effectiveness of any
sale, assignment or transfer that the assignee agree in writing to be bound by
the terms of this Agreement and the Note. The term “Lender” as used in this
letter agreement shall include any permitted assignee pursuant to this paragraph
6.

7. Miscellaneous. 

a. Any notice given hereunder shall be valid and effective only
if made in writing and delivered by U.S. certified mail, postage prepaid, or by
reputable overnight courier service, with a copy via facsimile or e-mail,
addressed as follows: 

	If to the Company: 	Primus Therapeutics, Inc. 
	  	23 Orchard Road, Suite 105 
	  	Princeton, NJ 08558-2644 
	  	Attention: Dennis M. O’Donnell 
	  	President & Chief Executive Officer 
	  	Telephone: (908) 601-1338 
	  	Facsimile: (360) 272-7472

	 	Email: dodonnell@primus.us.com

[Lender] 

[Date] 

Page 7 

	With a copy (which shall not 	Sheldrick & Co., PLLC 
	constitute notice) to: 	250 Park Avenue, Suite 700 
	  	New York, NY 10177 
	  	Attention: Andrew W. Sheldrick, Esq.
  
	  	Telephone: (646) 350-0469, ext 101 
	  	Facsimile: (646) 390-8724 
	  	Email: asheldrick@sheldricklaw.net 
	  	 
	If to Lender: 	[Lender] 
	  	[Address] 
	  	[Address] 
	  	Attention:
      [               
      ] 
	  	Telephone: (xxx) xxx-xxxx 
	  	Facsimile: (xxx) xxx-xxxx 
	  	Email:
      [            
      ] 

b. All questions concerning the construction, validity,
enforcement and interpretation of this letter agreement shall be governed by New
York law. Each party hereby irrevocably submits to the exclusive jurisdiction of
the state and federal courts sitting in The City of New York, Borough of
Manhattan, for the adjudication of any dispute hereunder or in connection
herewith or with any transaction contemplated hereby, and hereby irrevocably
waives, and agrees not to assert in any suit, action or proceeding, any claim
that it is not personally subject to the jurisdiction of any such court, that
such suit, action or proceeding is brought in an inconvenient forum or that the
venue of such suit, action or proceeding is improper. Each party hereby
irrevocably waives personal service of process and consents to process being
served in any such suit, action or proceeding by mailing a copy thereof to such
party at the address specified in Section 5.a. and agrees that such service
shall constitute good and sufficient service of process and notice thereof,
provided, however, that nothing contained herein shall be deemed to limit
in any way any right to serve process in any manner permitted by law. EACH PARTY
HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE, AND AGREES NOT TO REQUEST, A
JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION WITH
OR ARISING OUT OF THIS LETTER AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY.

c. This letter agreement may be executed in two or more
counterparts, all of which shall be considered one and the same agreement and
shall become effective when counterparts have been signed by each party and
delivered to the other party; provided that a facsimile signature shall be
considered due execution and shall be binding upon the signatory thereto with
the same force and effect as if the signature were an original, not a facsimile
signature. 

d. If any provision of this letter agreement shall be invalid
or unenforceable in any jurisdiction, such invalidity or unenforceability shall
not affect the validity or enforceability of the remainder of this letter agreement in
that jurisdiction or the validity or enforceability of any provision of this
letter agreement in any other jurisdiction. 

[Lender] 
[Date] 
Page 8 

e. The Transaction Documents contain the entire understanding
of the parties with respect to the matters covered herein and therein. No
provision of this letter agreement may be amended other than by an instrument in
writing signed by the Company and Lender.

f. This letter agreement is intended for the benefit of the
parties hereto and their respective permitted assigns and
successors-in-interest, and is not for the benefit of, nor may any provision
hereof be enforced by, any other person. 

g. The representations and warranties of Lender shall survive
the delivery of the Note and the issuance of the Conversion Shares.

h. The parties shall each do and perform, or cause to be done
and performed, all such further acts and things, and shall execute and deliver
all such other agreements, certificates, instruments and documents, as any other
party may reasonably request in order to carry out the intent and accomplish the
purposes of this letter agreement and the consummation of the transactions
contemplated hereby. 

i. The language used in this letter agreement shall be deemed
to be the language chosen by the parties to express their mutual intent, and no
rules of strict construction will be applied against any party. 

[Remainder of page intentionally blank] 

[Lender]
[Date]
Page 9 

Kindly confirm your agreement to the foregoing by signing one
counterpart of this letter agreement and return the same to the Company. 

Sincerely, 

PRIMUS
THERAPEUTICS, INC. 

By: 
_______________________
        [Name]

        [Title] 

 

	Amount of Loan:
      $[       ] 
	Lender’s Taxpayer ID Number: 
	Acknowledged and agreed this [  
       ] day of [    ], 2011: 
	[LENDER] 
	By:   _______________________
    
	Name: 

Exhibit A 

Form of Convertible Promissory
Note 

[See Attached] 

	
    
      THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS
      NOTE, AND THE SECURITIES INTO WHICH THEY ARE CONVERTIBLE, HAVE NOT BEEN
      REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE
      STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD,
      TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE
      REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF
      1933, AS AMENDED, OR (B) AN OPINION OF COUNSEL, IN A REASONABLY ACCEPTABLE
      FORM, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR (II) UNLESS SOLD
      PURSUANT TO RULE 144 UNDER SAID ACT. THIS NOTE MAY NOT BE SOLD, ASSIGNED
      OR OTHERERWISE TRANSFERRED OTHER THAN WITH THE CONSENT OF THE ISSUER IN
      ACCORDANCE WITH A LOAN AGEREMENT DATED JANUARY [ ], 2011 PURSUANT TO WHICH
      THIS NOTE IS ISSUED.
    

    

PRIMUS THERAPEUTICS, INC. 
CONVERTIBLE PROMISSORY NOTE

	Principal Amount: U.S. $[     ] 	Issuance Date: [Date ] 
	Interest Rate: 8% per annum 	Maturity Date: [2 Years Following Issuance
      Date] 

FOR VALUE RECEIVED, PRIMUS THERAPEUTICS, INC., a Delaware
corporation (the “Company”) hereby promises to pay to the order of
[Lender] or Lender’s permitted assigns (the “Holder”) the outstanding
Principal Amount of this Note upon the Maturity Date specified above, with
interest on the outstanding Principal Amount at the rate of eight percent (8%)
per annum, running from the Issuance Date specified above until the Principal
Amount and all accrued but unpaid Interest has been paid in full, whether upon
an Interest Payment Date (as defined in Section 1 below) or the Maturity Date.
This note (the “Note”) is issued pursuant to Section 1 of that certain
letter agreement between the Company and the Holder dated as of January 4, 2011
(the “Loan Agreement”), and the representations, warranties, covenants
and agreements set forth in the Loan Agreement are deemed incorporated herein by
reference. Capitalized terms used herein and not otherwise defined have the
meanings specified in the Loan Agreement. 

1. Interest. Interest on this Note shall commence
accruing on the Issuance Date and shall be computed on the basis of a 365-day
year and actual days elapsed and shall be payable in arrears to the holder of
record of this Note on the anniversary of the Issuance Date and quarterly
thereafter until this Note is repaid in full (each such date, an “Interest
Payment Date”). If any Interest Payment Date would, except for the
application of this sentence, falls on a day that is not a Business Day, the
Interest Payment Date shall be deemed to fall on the next succeeding Business
Day. 

2. Default Interest. Upon the occurrence of any Event of
Default as defined in Section 5.b(i) hereof, the Company shall pay, in addition
to the amount specified in Section 1 hereof, default interest at the rate of 5
percent (5%) on the principal amount of the loan then due and outstanding,
commencing from the date upon which the Event of Default occurs through and
including the day upon which all amounts then due have been paid in full or the
Event of Default has been cured, whichever shall first occur.

3. Prepayment. The Company may prepay the Principal
Amount, in whole or in part, together with interest thereon, without penalty or
make-whole payment, at any time, provided, however, that the Company shall not make any
such prepayment prior to [date that is thirteen months from date of
issuance].

4. Automatic Conversion. In the event that the Company
completes an Offering prior to the Maturity Date, the outstanding Loan Balance
shall automatically be converted, as of the closing of such Offering and without
further action by the Holder, into a number shares of the Company’s Common Stock
determined by dividing the outstanding Loan Balance as of the date upon which
the Offering is completed by the applicable Conversion Price.

5. Events of Default.

a. Upon the occurrence of any Event of Default as defined in
paragraph b. hereof, the Holder may, by written notice to the Company, declare
the outstanding Principal Amount of this Note, together with accrued interest
thereon, to be due and payable, and the outstanding Principal amount of this
Note together with such interest shall thereupon immediately become due and
payable without presentment, further notice, protest or other requirements of
any kind (all of which are hereby expressly waived by the Company.) The Company
shall pay to the Holder upon demand any costs and expenses of the Holder
(including, without limitation, reasonable attorneys’ fees) incurred in
collecting any amounts due pursuant to this Section 4.a. 

b. The following shall constitute an “Event of Default”
for purposes of this Note: 

	 	(i) 	The Company fails to pay any amount due on this Note within 5 Business
      Days of the due date; 
	 	 	 
	 	(ii) 	The Company fails to comply with or observe any material covenant or
      obligation under the Loan Agreement (including without limitation the
      obligation to issue the Conversion Shares) and such failure is not cured
      within five (5) days of the Company receiving written notice thereof from
      the Holder, unless the Lender has waived such default or granted any
      forbearance with respect thereto, in each case in writing; 
	 	 	 
	 	(iii) 	The Company is default of any material obligation under any other
      agreement for the borrowing of money, subject to any provisions regarding
      notice or cure under such other agreement, unless the obligee shall have
      granted any waiver or forbearance with respect thereto; 
	 	 	 
	 	(iv) 	Any representation or warranty of the Company given hereunder is
      materially untrue on the date as to which such representation or warranty
      is given; 

- 2 - 

	 	(v) 	Following the satisfaction of the Equity Condition, the Company shall
      fail to make any filing required under the Securities Exchange Act of 1934
      and the regulations promulgated thereunder, after giving effect to any
      extensions provided for therein; 
	 	 	 
	 	(vi) 	The Company shall generally fail to pay its debts as they become due;
    
	 	 	 
	 	(vii) 	The Company, pursuant to Title 11, U.S. Code, or any similar Federal
      or state law for the relief of debtors (collectively, “Bankruptcy
      Law”), (A) commences a voluntary case, (B) consents to the entry of an
      order for relief against it in an involuntary case, (C) consents to the
      appointment of a receiver, trustee, assignee, liquidator or similar
      official (a “Custodian”), or (D) makes a general assignment for the
      benefit of its; and 
	 	 	 
	 	(viii) 	A court of competent jurisdiction enters an order or decree under any
      Bankruptcy Law that (A) is for relief against the Company in an
      involuntary case, (B) appoints a Custodian of the Company or (C) orders
      the liquidation of the Company and such order or decree remains
      undismissed or unstayed for a period of sixty (60) days.

6. Transfer. This Note may be not be offered, sold,
assigned or transferred by the Holder without the written consent of the Company
in accordance with the provisions set forth in the Loan Agreement. 

8. Security. This Note shall not be secured.

9. Construction; Headings. This Note shall be deemed to
be jointly drafted by the Company and the Holder and shall not be construed
against any Person as the drafter hereof. The headings of this Note are for
convenience of reference and shall not form part of, or affect the
interpretation of, this Note. 

7. Failure of Indulgence or Waiver. No failure or delay
on the part of the Holder in the exercise of any power, right or privilege
hereunder shall operate as a waiver thereof, nor shall any single or partial
exercise of any such power, right or privilege preclude other or further
exercise thereof or of any other right, power or privilege. 

8. Notices. Whenever notice is required to be given
under this Note, unless otherwise provided herein, such notice shall be given in
accordance with Section 5.a. of the Loan Agreement. 

- 3 - 

9. Waiver of Notice. To the extent permitted by law, the
Company hereby waives demand, notice, protest and all other demands and notices
in connection with the delivery, acceptance, performance, default or enforcement
of this Note. 

10. Governing Law; Jurisdiction; Jury Trial. This Note
shall be construed and enforced in accordance with New York law. Each of the
parties hereto irrevocably submits to the exclusive jurisdiction of the state
and federal courts sitting in the City of New York, Borough of Manhattan, for
the adjudication of any dispute arising hereunder or in connection herewith and
hereby irrevocably waives, and agrees not to assert in any suit, action or
proceeding, any claim that it is not personally subject to the jurisdiction of
any such court, that such suit, action or proceeding is brought in an
inconvenient forum or that the venue of such suit, action or proceeding is
improper. Each of the parties hereto irrevocably waives personal service of
process and consents to process being served in any such suit, action or
proceeding by mailing a copy thereof at the address set forth in Section 5.a. of
the Loan Agreement, or in the case of a transferee of any Note, at such address
as is provided to the Company by such holder at the time of such transfer, and
agrees that such service shall constitute good and sufficient service of process
and notice thereof. Nothing contained herein shall be deemed to limit in any way
any right to serve process in any manner permitted by law. In the event that any
provision of this Note is invalid or unenforceable under any applicable statute
or rule of law, then such provision shall be deemed inoperative to the extent
that it may conflict therewith and shall be deemed modified to conform with such
statute or rule of law. Any such provision that may prove invalid or
unenforceable under any law shall not affect the validity or enforceability of
any other provision of this Note. EACH OF THE COMPANY AND THE HOLDER HEREBY
IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE, AND AGREES NOT TO REQUEST, A JURY
TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION WITH OR
ARISING OUT OF THIS NOTE OR ANY TRANSACTION CONTEMPLATED HEREBY. 

IN WITNESS WHEREOF, the Company has caused this Note to be duly
executed as of the Issuance Date specified above. 

PRIMUS THERAPEUTICS, INC. 

By: 
_______________________
        [Name]

        [Title] 

- 4 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00184-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00184-of-00352.parquet"}]]